A collaboration between Otsuka America Pharmaceutical and Magellan Health is the latest example of how the line between pharma and medtech continues to blur.
News & Features
With all of the indications Avinger is pursuing, it seems as if the Redwood City, CA-based company has an ‘infinite’ number of approaches in treating peripheral arterial disease patients.
A few months back, a Needham & Co. analyst noted that K2M was one of the 25 most attractive medtech companies on the M&A radar.
The Mason, OH-based company said it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial.
The San Jose, CA-based company is seeking to redefine and simplify Hemodialysis through its Tablo device.
Removing the CyPass Micro-Stent from the market is in patients' best interests, and is "the right thing to do," said Alcon's chief medical officer, after five-year data revealed a higher rate of cell loss compared to patients who had cataract surgery alone.
A man in Texas has filed a class action lawsuit claiming that Boston Scientific made unsolicited, prerecorded voice sales calls to him, even though his number is registered on the National Do Not Call list.
The founders of Fuzionaire Dx talked to MD+DI about how a chemistry breakthrough led to the formation of the company and attracted the help of Michael Phelps, the original inventor of the PET scanner.